search
Back to results

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
BI 10773
BI 10773 Placebo
BI 10773 / BI 1356
BI 10773
BI 10773 / BI 1356
BI 10773 / BI 1356 Placebo
BI 10773
BI 10773
BI 10773
BI 10773 / BI 1356 Placebo
BI 10773 Placebo
BI 10773 / BI 1356 Placebo
BI 10773
BI 10773 / BI 1356 Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Signed and dated ICF (Informed Consent Form)
  2. Male or female on diet and exercise regime and on stable background metformin > or equal to 1500 mg or maximun dose according to local label
  3. HBA1c (Glicoslated Hemoglobin) > or equal to 8% and < or equal to 10.5 % at Visit 1
  4. HbA1c > or equal to 7 and < or equal to 10.5 at Visit 4
  5. Age > or equal to 18 years
  6. BMI (Body Mass Index) < or equal to 45

Exclusion criteria:

  1. Uncontrolled hyperglycemia during open label period and placebo add on "run-in" period
  2. Use of any other antidiabetic
  3. Renal function below 60 ml/min/1.73 m2
  4. Antiobesity drugs or aggresive diets
  5. Gastorintestinal surgeries
  6. Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2
  7. Acute coronary syndrome and stroke within 3 months of informed consent
  8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors

Sites / Locations

  • 1275.10.01019 Boehringer Ingelheim Investigational Site
  • 1275.10.01008 Boehringer Ingelheim Investigational Site
  • 1275.10.01003 Boehringer Ingelheim Investigational Site
  • 1275.10.01024 Boehringer Ingelheim Investigational Site
  • 1275.10.01002 Boehringer Ingelheim Investigational Site
  • 1275.10.01011 Boehringer Ingelheim Investigational Site
  • 1275.10.01009 Boehringer Ingelheim Investigational Site
  • 1275.10.01023 Boehringer Ingelheim Investigational Site
  • 1275.10.01006 Boehringer Ingelheim Investigational Site
  • 1275.10.01017 Boehringer Ingelheim Investigational Site
  • 1275.10.01016 Boehringer Ingelheim Investigational Site
  • 1275.10.01012 Boehringer Ingelheim Investigational Site
  • 1275.10.01013 Boehringer Ingelheim Investigational Site
  • 1275.10.01010 Boehringer Ingelheim Investigational Site
  • 1275.10.01001 Boehringer Ingelheim Investigational Site
  • 1275.10.01007 Boehringer Ingelheim Investigational Site
  • 1275.10.01005 Boehringer Ingelheim Investigational Site
  • 1275.10.01020 Boehringer Ingelheim Investigational Site
  • 1275.10.01022 Boehringer Ingelheim Investigational Site
  • 1275.10.01021 Boehringer Ingelheim Investigational Site
  • 1275.10.01014 Boehringer Ingelheim Investigational Site
  • 1275.10.01018 Boehringer Ingelheim Investigational Site
  • 1275.10.01015 Boehringer Ingelheim Investigational Site
  • 1275.10.01025 Boehringer Ingelheim Investigational Site
  • 1275.10.54005 Boehringer Ingelheim Investigational Site
  • 1275.10.54012 Boehringer Ingelheim Investigational Site
  • 1275.10.54002 Boehringer Ingelheim Investigational Site
  • 1275.10.54007 Boehringer Ingelheim Investigational Site
  • 1275.10.54013 Boehringer Ingelheim Investigational Site
  • 1275.10.54006 Boehringer Ingelheim Investigational Site
  • 1275.10.54008 Boehringer Ingelheim Investigational Site
  • 1275.10.54011 Boehringer Ingelheim Investigational Site
  • 1275.10.54003 Boehringer Ingelheim Investigational Site
  • 1275.10.54009 Boehringer Ingelheim Investigational Site
  • 1275.10.54004 Boehringer Ingelheim Investigational Site
  • 1275.10.54001 Boehringer Ingelheim Investigational Site
  • 1275.10.54010 Boehringer Ingelheim Investigational Site
  • 1275.10.61008 Boehringer Ingelheim Investigational Site
  • 1275.10.61002 Boehringer Ingelheim Investigational Site
  • 1275.10.61001 Boehringer Ingelheim Investigational Site
  • 1275.10.61009 Boehringer Ingelheim Investigational Site
  • 1275.10.02004 Boehringer Ingelheim Investigational Site
  • 1275.10.02001 Boehringer Ingelheim Investigational Site
  • 1275.10.02003 Boehringer Ingelheim Investigational Site
  • 1275.10.02009 Boehringer Ingelheim Investigational Site
  • 1275.10.02012 Boehringer Ingelheim Investigational Site
  • 1275.10.02006 Boehringer Ingelheim Investigational Site
  • 1275.10.02008 Boehringer Ingelheim Investigational Site
  • 1275.10.02005 Boehringer Ingelheim Investigational Site
  • 1275.10.02013 Boehringer Ingelheim Investigational Site
  • 1275.10.02002 Boehringer Ingelheim Investigational Site
  • 1275.10.02007 Boehringer Ingelheim Investigational Site
  • 1275.10.02011 Boehringer Ingelheim Investigational Site
  • 1275.10.02010 Boehringer Ingelheim Investigational Site
  • 1275.10.34014 Boehringer Ingelheim Investigational Site
  • 1275.10.49007 Boehringer Ingelheim Investigational Site
  • 1275.10.49014 Boehringer Ingelheim Investigational Site
  • 1275.10.49016 Boehringer Ingelheim Investigational Site
  • 1275.10.49012 Boehringer Ingelheim Investigational Site
  • 1275.10.49005 Boehringer Ingelheim Investigational Site
  • 1275.10.49008 Boehringer Ingelheim Investigational Site
  • 1275.10.49004 Boehringer Ingelheim Investigational Site
  • 1275.10.49010 Boehringer Ingelheim Investigational Site
  • 1275.10.49003 Boehringer Ingelheim Investigational Site
  • 1275.10.49006 Boehringer Ingelheim Investigational Site
  • 1275.10.49013 Boehringer Ingelheim Investigational Site
  • 1275.10.49001 Boehringer Ingelheim Investigational Site
  • 1275.10.49015 Boehringer Ingelheim Investigational Site
  • 1275.10.39005 Boehringer Ingelheim Investigational Site
  • 1275.10.39006 Boehringer Ingelheim Investigational Site
  • 1275.10.39009 Boehringer Ingelheim Investigational Site
  • 1275.10.39014 Boehringer Ingelheim Investigational Site
  • 1275.10.39007 Boehringer Ingelheim Investigational Site
  • 1275.10.39012 Boehringer Ingelheim Investigational Site
  • 1275.10.39013 Boehringer Ingelheim Investigational Site
  • 1275.10.39015 Boehringer Ingelheim Investigational Site
  • 1275.10.39016 Boehringer Ingelheim Investigational Site
  • 1275.10.39004 Boehringer Ingelheim Investigational Site
  • 1275.10.39003 Boehringer Ingelheim Investigational Site
  • 1275.10.39008 Boehringer Ingelheim Investigational Site
  • 1275.10.39001 Boehringer Ingelheim Investigational Site
  • 1275.10.39010 Boehringer Ingelheim Investigational Site
  • 1275.10.39011 Boehringer Ingelheim Investigational Site
  • 1275.10.35104 Boehringer Ingelheim Investigational Site
  • 1275.10.35112 Boehringer Ingelheim Investigational Site
  • 1275.10.35103 Boehringer Ingelheim Investigational Site
  • 1275.10.35105 Boehringer Ingelheim Investigational Site
  • 1275.10.35108 Boehringer Ingelheim Investigational Site
  • 1275.10.35101 Boehringer Ingelheim Investigational Site
  • 1275.10.07004 Boehringer Ingelheim Investigational Site
  • 1275.10.07006 Boehringer Ingelheim Investigational Site
  • 1275.10.07001 Boehringer Ingelheim Investigational Site
  • 1275.10.07005 Boehringer Ingelheim Investigational Site
  • 1275.10.07003 Boehringer Ingelheim Investigational Site
  • 1275.10.07002 Boehringer Ingelheim Investigational Site
  • 1275.10.34003 Boehringer Ingelheim Investigational Site
  • 1275.10.34004 Boehringer Ingelheim Investigational Site
  • 1275.10.34008 Boehringer Ingelheim Investigational Site
  • 1275.10.34009 Boehringer Ingelheim Investigational Site
  • 1275.10.34012 Boehringer Ingelheim Investigational Site
  • 1275.10.34006 Boehringer Ingelheim Investigational Site
  • 1275.10.34010 Boehringer Ingelheim Investigational Site
  • 1275.10.34011 Boehringer Ingelheim Investigational Site
  • 1275.10.34001 Boehringer Ingelheim Investigational Site
  • 1275.10.34013 Boehringer Ingelheim Investigational Site
  • 1275.10.34002 Boehringer Ingelheim Investigational Site
  • 1275.10.34005 Boehringer Ingelheim Investigational Site
  • 1275.10.38006 Boehringer Ingelheim Investigational Site
  • 1275.10.38007 Boehringer Ingelheim Investigational Site
  • 1275.10.38002 Boehringer Ingelheim Investigational Site
  • 1275.10.38003 Boehringer Ingelheim Investigational Site
  • 1275.10.38004 Boehringer Ingelheim Investigational Site
  • 1275.10.38001 Boehringer Ingelheim Investigational Site
  • 1275.10.38005 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Empagliflozin 10 mg dose

Placebo add on 10 mg dose

Empagliflozin/Linagliptin 25/5 mg Dose

Empagliflozin/Linagliptin 10/5 mg Dose.

Empagliflozin/Linagliptin 10/5 mg Dose

Empagliflozin 25 mg dose

Empagliflozin/Linagliptin 25/5 mg Dose.

Placebo add on 25 mg dose

Arm Description

Empagliflozin open label treatment period

Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in

Empagliflozin / Linagliptin 25/5 mg Dose FDC active

Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo

Empagliflozin / Linagliptin 10/5 mg Dose FDC active

Empagliflozin open label treatment period

Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo

Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in

Outcomes

Primary Outcome Measures

Change From Baseline of HbA1c After 24 Weeks of Treatment.
Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.

Secondary Outcome Measures

Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.
Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.

Full Information

First Posted
January 24, 2013
Last Updated
March 4, 2016
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01778049
Brief Title
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Official Title
A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company

4. Oversight

5. Study Description

Brief Summary
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary objective of efficacy evaluation is planned after 24 weeks of treatment. The study is designed to show superiority of the combination of empagliflozin and linagliptin over empagliflozin alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
708 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Empagliflozin 10 mg dose
Arm Type
Experimental
Arm Description
Empagliflozin open label treatment period
Arm Title
Placebo add on 10 mg dose
Arm Type
Experimental
Arm Description
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
Arm Title
Empagliflozin/Linagliptin 25/5 mg Dose
Arm Type
Experimental
Arm Description
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Arm Title
Empagliflozin/Linagliptin 10/5 mg Dose.
Arm Type
Experimental
Arm Description
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Arm Title
Empagliflozin/Linagliptin 10/5 mg Dose
Arm Type
Experimental
Arm Description
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Arm Title
Empagliflozin 25 mg dose
Arm Type
Experimental
Arm Description
Empagliflozin open label treatment period
Arm Title
Empagliflozin/Linagliptin 25/5 mg Dose.
Arm Type
Experimental
Arm Description
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Arm Title
Placebo add on 25 mg dose
Arm Type
Experimental
Arm Description
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
Empagliflozin active
Intervention Type
Drug
Intervention Name(s)
BI 10773 Placebo
Intervention Description
Empagliflozin placebo
Intervention Type
Drug
Intervention Name(s)
BI 10773 / BI 1356
Intervention Description
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
Empagliflozin active
Intervention Type
Drug
Intervention Name(s)
BI 10773 / BI 1356
Intervention Description
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Intervention Type
Drug
Intervention Name(s)
BI 10773 / BI 1356 Placebo
Intervention Description
Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
Empagliflozin active
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
Empagliflozin active
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
Empagliflozin active
Intervention Type
Drug
Intervention Name(s)
BI 10773 / BI 1356 Placebo
Intervention Description
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Intervention Type
Drug
Intervention Name(s)
BI 10773 Placebo
Intervention Description
Empagliflozin placebo
Intervention Type
Drug
Intervention Name(s)
BI 10773 / BI 1356 Placebo
Intervention Description
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
Empagliflozin active
Intervention Type
Drug
Intervention Name(s)
BI 10773 / BI 1356 Placebo
Intervention Description
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Primary Outcome Measure Information:
Title
Change From Baseline of HbA1c After 24 Weeks of Treatment.
Description
Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.
Time Frame
Baseline and 24 weeks
Secondary Outcome Measure Information:
Title
Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.
Description
Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.
Time Frame
Baseline and 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Signed and dated ICF (Informed Consent Form) Male or female on diet and exercise regime and on stable background metformin > or equal to 1500 mg or maximun dose according to local label HBA1c (Glicoslated Hemoglobin) > or equal to 8% and < or equal to 10.5 % at Visit 1 HbA1c > or equal to 7 and < or equal to 10.5 at Visit 4 Age > or equal to 18 years BMI (Body Mass Index) < or equal to 45 Exclusion criteria: Uncontrolled hyperglycemia during open label period and placebo add on "run-in" period Use of any other antidiabetic Renal function below 60 ml/min/1.73 m2 Antiobesity drugs or aggresive diets Gastorintestinal surgeries Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2 Acute coronary syndrome and stroke within 3 months of informed consent Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1275.10.01019 Boehringer Ingelheim Investigational Site
City
Chino
State/Province
California
Country
United States
Facility Name
1275.10.01008 Boehringer Ingelheim Investigational Site
City
Huntington Beach
State/Province
California
Country
United States
Facility Name
1275.10.01003 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1275.10.01024 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1275.10.01002 Boehringer Ingelheim Investigational Site
City
Sylmar
State/Province
California
Country
United States
Facility Name
1275.10.01011 Boehringer Ingelheim Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
1275.10.01009 Boehringer Ingelheim Investigational Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
1275.10.01023 Boehringer Ingelheim Investigational Site
City
Oviedo
State/Province
Florida
Country
United States
Facility Name
1275.10.01006 Boehringer Ingelheim Investigational Site
City
Tamarac
State/Province
Florida
Country
United States
Facility Name
1275.10.01017 Boehringer Ingelheim Investigational Site
City
Conyers
State/Province
Georgia
Country
United States
Facility Name
1275.10.01016 Boehringer Ingelheim Investigational Site
City
Snellville
State/Province
Georgia
Country
United States
Facility Name
1275.10.01012 Boehringer Ingelheim Investigational Site
City
Avon
State/Province
Indiana
Country
United States
Facility Name
1275.10.01013 Boehringer Ingelheim Investigational Site
City
Muncie
State/Province
Indiana
Country
United States
Facility Name
1275.10.01010 Boehringer Ingelheim Investigational Site
City
Elkton
State/Province
Maryland
Country
United States
Facility Name
1275.10.01001 Boehringer Ingelheim Investigational Site
City
Stevensville
State/Province
Michigan
Country
United States
Facility Name
1275.10.01007 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
North Carolina
Country
United States
Facility Name
1275.10.01005 Boehringer Ingelheim Investigational Site
City
Bismarck
State/Province
North Dakota
Country
United States
Facility Name
1275.10.01020 Boehringer Ingelheim Investigational Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
1275.10.01022 Boehringer Ingelheim Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
1275.10.01021 Boehringer Ingelheim Investigational Site
City
Union
State/Province
South Carolina
Country
United States
Facility Name
1275.10.01014 Boehringer Ingelheim Investigational Site
City
North Richland Hills
State/Province
Texas
Country
United States
Facility Name
1275.10.01018 Boehringer Ingelheim Investigational Site
City
Draper
State/Province
Utah
Country
United States
Facility Name
1275.10.01015 Boehringer Ingelheim Investigational Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
1275.10.01025 Boehringer Ingelheim Investigational Site
City
Virginia Beach
State/Province
Virginia
Country
United States
Facility Name
1275.10.54005 Boehringer Ingelheim Investigational Site
City
Caba
Country
Argentina
Facility Name
1275.10.54012 Boehringer Ingelheim Investigational Site
City
Caba
Country
Argentina
Facility Name
1275.10.54002 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1275.10.54007 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1275.10.54013 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1275.10.54006 Boehringer Ingelheim Investigational Site
City
Cordoba
Country
Argentina
Facility Name
1275.10.54008 Boehringer Ingelheim Investigational Site
City
Cordoba
Country
Argentina
Facility Name
1275.10.54011 Boehringer Ingelheim Investigational Site
City
Córdoba
Country
Argentina
Facility Name
1275.10.54003 Boehringer Ingelheim Investigational Site
City
Godoy Cruz, Mendoza
Country
Argentina
Facility Name
1275.10.54009 Boehringer Ingelheim Investigational Site
City
Mar del Plata
Country
Argentina
Facility Name
1275.10.54004 Boehringer Ingelheim Investigational Site
City
Salta
Country
Argentina
Facility Name
1275.10.54001 Boehringer Ingelheim Investigational Site
City
San Isidro
Country
Argentina
Facility Name
1275.10.54010 Boehringer Ingelheim Investigational Site
City
Zarate
Country
Argentina
Facility Name
1275.10.61008 Boehringer Ingelheim Investigational Site
City
Cardiff
State/Province
New South Wales
Country
Australia
Facility Name
1275.10.61002 Boehringer Ingelheim Investigational Site
City
East Ringwood
State/Province
Victoria
Country
Australia
Facility Name
1275.10.61001 Boehringer Ingelheim Investigational Site
City
Heidelberg Heights
State/Province
Victoria
Country
Australia
Facility Name
1275.10.61009 Boehringer Ingelheim Investigational Site
City
Mirrabooka
State/Province
Western Australia
Country
Australia
Facility Name
1275.10.02004 Boehringer Ingelheim Investigational Site
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
1275.10.02001 Boehringer Ingelheim Investigational Site
City
Red Deer
State/Province
Alberta
Country
Canada
Facility Name
1275.10.02003 Boehringer Ingelheim Investigational Site
City
Chilliwack
State/Province
British Columbia
Country
Canada
Facility Name
1275.10.02009 Boehringer Ingelheim Investigational Site
City
Coquitlam
State/Province
British Columbia
Country
Canada
Facility Name
1275.10.02012 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
1275.10.02006 Boehringer Ingelheim Investigational Site
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
1275.10.02008 Boehringer Ingelheim Investigational Site
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
1275.10.02005 Boehringer Ingelheim Investigational Site
City
Moncton
State/Province
New Brunswick
Country
Canada
Facility Name
1275.10.02013 Boehringer Ingelheim Investigational Site
City
Burlington
State/Province
Ontario
Country
Canada
Facility Name
1275.10.02002 Boehringer Ingelheim Investigational Site
City
Strathroy
State/Province
Ontario
Country
Canada
Facility Name
1275.10.02007 Boehringer Ingelheim Investigational Site
City
Sudbury
State/Province
Ontario
Country
Canada
Facility Name
1275.10.02011 Boehringer Ingelheim Investigational Site
City
Drummondville
State/Province
Quebec
Country
Canada
Facility Name
1275.10.02010 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1275.10.34014 Boehringer Ingelheim Investigational Site
City
Ávila
Country
El Salvador
Facility Name
1275.10.49007 Boehringer Ingelheim Investigational Site
City
Asslar
Country
Germany
Facility Name
1275.10.49014 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1275.10.49016 Boehringer Ingelheim Investigational Site
City
Elsterwerda
Country
Germany
Facility Name
1275.10.49012 Boehringer Ingelheim Investigational Site
City
Hamburg
Country
Germany
Facility Name
1275.10.49005 Boehringer Ingelheim Investigational Site
City
Hatten
Country
Germany
Facility Name
1275.10.49008 Boehringer Ingelheim Investigational Site
City
Kiel Kronshagen
Country
Germany
Facility Name
1275.10.49004 Boehringer Ingelheim Investigational Site
City
Köln
Country
Germany
Facility Name
1275.10.49010 Boehringer Ingelheim Investigational Site
City
Lübeck
Country
Germany
Facility Name
1275.10.49003 Boehringer Ingelheim Investigational Site
City
Münster
Country
Germany
Facility Name
1275.10.49006 Boehringer Ingelheim Investigational Site
City
Pirna
Country
Germany
Facility Name
1275.10.49013 Boehringer Ingelheim Investigational Site
City
St. Ingbert/Oberwürzbach
Country
Germany
Facility Name
1275.10.49001 Boehringer Ingelheim Investigational Site
City
Unterschneidheim
Country
Germany
Facility Name
1275.10.49015 Boehringer Ingelheim Investigational Site
City
Wangen
Country
Germany
Facility Name
1275.10.39005 Boehringer Ingelheim Investigational Site
City
Ancona
Country
Italy
Facility Name
1275.10.39006 Boehringer Ingelheim Investigational Site
City
Catania
Country
Italy
Facility Name
1275.10.39009 Boehringer Ingelheim Investigational Site
City
Catania
Country
Italy
Facility Name
1275.10.39014 Boehringer Ingelheim Investigational Site
City
Catania
Country
Italy
Facility Name
1275.10.39007 Boehringer Ingelheim Investigational Site
City
Latina
Country
Italy
Facility Name
1275.10.39012 Boehringer Ingelheim Investigational Site
City
Milano
Country
Italy
Facility Name
1275.10.39013 Boehringer Ingelheim Investigational Site
City
Milano
Country
Italy
Facility Name
1275.10.39015 Boehringer Ingelheim Investigational Site
City
Olbia (OT)
Country
Italy
Facility Name
1275.10.39016 Boehringer Ingelheim Investigational Site
City
Orbassano (TO)
Country
Italy
Facility Name
1275.10.39004 Boehringer Ingelheim Investigational Site
City
Palermo
Country
Italy
Facility Name
1275.10.39003 Boehringer Ingelheim Investigational Site
City
Pistoia
Country
Italy
Facility Name
1275.10.39008 Boehringer Ingelheim Investigational Site
City
Roma
Country
Italy
Facility Name
1275.10.39001 Boehringer Ingelheim Investigational Site
City
Sesto San Giovanni (MI)
Country
Italy
Facility Name
1275.10.39010 Boehringer Ingelheim Investigational Site
City
Siena
Country
Italy
Facility Name
1275.10.39011 Boehringer Ingelheim Investigational Site
City
Terni
Country
Italy
Facility Name
1275.10.35104 Boehringer Ingelheim Investigational Site
City
Cantanhede
Country
Portugal
Facility Name
1275.10.35112 Boehringer Ingelheim Investigational Site
City
Porto
Country
Portugal
Facility Name
1275.10.35103 Boehringer Ingelheim Investigational Site
City
Sandim
Country
Portugal
Facility Name
1275.10.35105 Boehringer Ingelheim Investigational Site
City
Tornada
Country
Portugal
Facility Name
1275.10.35108 Boehringer Ingelheim Investigational Site
City
Valadares
Country
Portugal
Facility Name
1275.10.35101 Boehringer Ingelheim Investigational Site
City
Vila Nova de Gaia
Country
Portugal
Facility Name
1275.10.07004 Boehringer Ingelheim Investigational Site
City
Chelyabinsk
Country
Russian Federation
Facility Name
1275.10.07006 Boehringer Ingelheim Investigational Site
City
Saint-Petersburg
Country
Russian Federation
Facility Name
1275.10.07001 Boehringer Ingelheim Investigational Site
City
Saratov
Country
Russian Federation
Facility Name
1275.10.07005 Boehringer Ingelheim Investigational Site
City
Saratov
Country
Russian Federation
Facility Name
1275.10.07003 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1275.10.07002 Boehringer Ingelheim Investigational Site
City
Yaroslavl
Country
Russian Federation
Facility Name
1275.10.34003 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1275.10.34004 Boehringer Ingelheim Investigational Site
City
Canet de Mar
Country
Spain
Facility Name
1275.10.34008 Boehringer Ingelheim Investigational Site
City
Centelles
Country
Spain
Facility Name
1275.10.34009 Boehringer Ingelheim Investigational Site
City
L'Hospitalet de Llobregat (Barcelona)
Country
Spain
Facility Name
1275.10.34012 Boehringer Ingelheim Investigational Site
City
La Roca del Vallès
Country
Spain
Facility Name
1275.10.34006 Boehringer Ingelheim Investigational Site
City
Madrid
Country
Spain
Facility Name
1275.10.34010 Boehringer Ingelheim Investigational Site
City
Malaga
Country
Spain
Facility Name
1275.10.34011 Boehringer Ingelheim Investigational Site
City
Mataró
Country
Spain
Facility Name
1275.10.34001 Boehringer Ingelheim Investigational Site
City
Málaga
Country
Spain
Facility Name
1275.10.34013 Boehringer Ingelheim Investigational Site
City
Pineda de Mar
Country
Spain
Facility Name
1275.10.34002 Boehringer Ingelheim Investigational Site
City
Sabadell
Country
Spain
Facility Name
1275.10.34005 Boehringer Ingelheim Investigational Site
City
Tarragona
Country
Spain
Facility Name
1275.10.38006 Boehringer Ingelheim Investigational Site
City
Chernivtsi
Country
Ukraine
Facility Name
1275.10.38007 Boehringer Ingelheim Investigational Site
City
Dnipropetrovs'k
Country
Ukraine
Facility Name
1275.10.38002 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1275.10.38003 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1275.10.38004 Boehringer Ingelheim Investigational Site
City
Lviv
Country
Ukraine
Facility Name
1275.10.38001 Boehringer Ingelheim Investigational Site
City
Vinnitsa
Country
Ukraine
Facility Name
1275.10.38005 Boehringer Ingelheim Investigational Site
City
Zhytomyr
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
27762093
Citation
Tinahones FJ, Gallwitz B, Nordaby M, Gotz S, Maldonado-Lutomirsky M, Woerle HJ, Broedl UC. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes Obes Metab. 2017 Feb;19(2):266-274. doi: 10.1111/dom.12814. Epub 2016 Nov 24.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info

Learn more about this trial

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

We'll reach out to this number within 24 hrs